Multiple Sclerosis Fatigue (Investigational Adjunct)
Investigational adjunct for MS-related fatigue; no clinical study was identified; disease-modifying therapy and modafinil/amantadine remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for multiple sclerosis fatigue. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for multiple sclerosis or MS fatigue was identified. Evidence-based first-line management of MS fatigue is optimization of disease-modifying therapy, treatment of comorbid sleep disorders, depression, and thyroid disease, structured aerobic exercise, and (with mixed but real evidence) amantadine, modafinil, or methylphenidate. Cognitive behavioral therapy specifically for MS fatigue also has RCT support.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Worsening of MS-related dysautonomia (orthostatic symptoms) after a session that draws blood volume
- Uhthoff phenomenon (heat-induced symptom worsening) if the session room is warm
- Who should not consider this
- Patients in an active MS relapse (focus must be on the relapse, not adjunctive therapy)
- Patients who have not had MS-specific fatigue evaluated for treatable mimics: anemia, hypothyroidism, depression, sleep apnea
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- Patients who are pregnant (leech therapy is not done during pregnancy) or breastfeeding (discuss it with your doctor)
- What to ask your clinician
- Has my fatigue been worked up for treatable causes — anemia, low thyroid, sleep apnea, depression?
- Am I on optimal disease-modifying therapy for my MS subtype?
- Have I tried amantadine, modafinil, or methylphenidate?
- What CBT or graded exercise programs for MS fatigue are available?
- What is the published evidence base for leeches in MS fatigue specifically?
- Could blood loss from sessions worsen my fatigue rather than help it?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- New or worsening neurologic symptoms — vision change, weakness, numbness, balance loss, bladder problems (possible MS relapse)
- Severe orthostatic dizziness or fainting on standing
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for MS fatigue — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace MS disease-modifying therapy, which targets the underlying disease.
- It does not address common reversible causes of fatigue such as anemia, thyroid disease, depression, or sleep apnea.
- It has no identified clinical evidence of any kind in MS, controlled or uncontrolled.
- It does not modify MS disease activity or progression in any way.
Safety cross-references
Clinical Profile
- Category
- Neurological
- ICD-10
- G35, R53.83
- Safety tier
- High
Evidence Summary
MS fatigue is among the most disabling symptoms in multiple sclerosis. Management per AAN guidance includes addressing depression and sleep disorders, exercise therapy, and pharmacotherapy (amantadine, modafinil, methylphenidate - all off-label, with modest effect sizes). No clinical study of leech therapy for multiple sclerosis or MS-related fatigue was identified in PubMed, Europe PMC, ClinicalTrials.gov, Russian-language sources or the Baskova and Isakhanyan 2004 monograph, which only lists MS among conditions for which leeches had been recommended (Bottenberg 1983) without presenting data; use is investigational only. Although an antiinflammatory rationale is sometimes proposed given the immune-mediated nature of MS, there is no clinical evidence to support it. Important: MS patients on natalizumab or other immunosuppressants face increased infection risk, complicating Aeromonas prophylaxis decisions.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan name multiple sclerosis only once and only in a list: according to the conclusion by Bottenberg (1983) that they cite, the method is indicated in a number of nervous diseases, among them multiple sclerosis; there is no description of treatment, patient numbers or results there[B1].
- Neither book writes about fatigue in multiple sclerosis: in Baskova and Isakhanyan the words fatigue and asthenia occur only in descriptions of other conditions, and in Michalsen et al. there is no multiple sclerosis at all[B1][B3].
- Flecken and Michalsen (Chapter 8) write that in severe unstable organ disease or marked immunosuppression (chemotherapy) hirudotherapy is never performed, and they classify immune diseases and connective tissue diseases as relative contraindications; multiple sclerosis is not named in their book, and whether it belongs to “immune diseases” is not clear from the text[B3].
- Among the contraindications, Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemia, low blood pressure, acute vascular insufficiency (shock, collapse, fainting), exhaustion (cachexia), concurrent use of anticoagulants and alcohol, and individual intolerance; they advise refraining when body temperature is high, call the question of pregnancy open, and regard prescribing leeches in large numbers, for long periods, without breaks or with short breaks as unjustified and impermissible[B1].
- Flecken and Michalsen (Chapter 8) call hemophilia and the use of anticoagulants an absolute contraindication, write that aspirin and clopidogrel are not in themselves a contraindication (in which case fewer leeches are needed at the first session), and that in anemia and in pregnancy treatment involving blood loss is, as a rule, contraindicated; this is only part of the contraindications listed in the books[B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active MS relapse (treat with corticosteroids first)
- Severe immunosuppression from DMT (natalizumab, alemtuzumab)
- Active urinary tract infection (common in MS)
- Decubitus ulcers or skin breakdown over treatment sites
Related Conditions
Chronic Fatigue Syndrome / ME (Investigational)
Investigational adjunct for myalgic encephalomyelitis/chronic fatigue syndrome; no clinical study identified; conventional pacing and symptom management remain primary.
Fibromyalgia
Investigational use only: no controlled clinical study of leech therapy for fibromyalgia was identified, and it is not a primary treatment.
Post-Stroke Hemiplegia (Investigational Adjunct)
Investigational adjunct to physical/occupational therapy in chronic post-stroke hemiplegia; no RCT support; not for acute stroke care.
Cervical Radiculopathy
Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.